文献速递泌尿男性生殖肿瘤

阿昔替尼对比安慰剂辅助治疗肾细胞癌:III期随机ATLAS试验结果

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
PubMed 文献 · Ann Oncol · 2018-01-01

ATLAS是一项III期随机双盲试验,纳入724例肾切除术后高危复发肾细胞癌患者,比较阿昔替尼5mg每日两次口服(≤3年)与安慰剂的疗效。主要终点为IRC评估的无病生存期(DFS),因中期分析无效而提前终止;IRC评估DFS无显著差异(HR=0.870,95%CI 0.660-1.147,P=0.3211),但在最高危亚组中研究者评估DFS风险降低36%(HR=0.641,95%CI 0.468-0.879,P=0.0051)。

要点

  • ATLAS试验因无效提前终止,主要终点IRC评估DFS未达显著差异。
  • 最高危亚组(pT3且FG≥3或pT4和/或N+)研究者评估DFS风险降低36%。
  • 阿昔替尼组3/4级不良事件发生率高于安慰剂组(61% vs 30%)。

核心结论

  • ATLAS试验未达到主要终点,IRC评估的DFS在阿昔替尼与安慰剂间无显著差异。
  • 最高危亚组中研究者评估DFS见改善,但IRC评估未达统计学显著。
  • 未报告新的安全性信号。

研究设计与样本

  • III期随机双盲试验,纳入724例肾切除术后无宏观残留或转移性疾病的肾细胞癌患者。
  • 患者按1:1随机接受口服阿昔替尼5mg每日两次或安慰剂,最长3年(至少1年)。

主要发现

  • IRC评估DFS:HR=0.870(95%CI 0.660-1.147,P=0.3211),无显著差异。
  • 最高危亚组研究者评估DFS事件风险降低36%(HR=0.641,95%CI 0.468-0.879,P=0.0051)。
  • 最高危亚组IRC评估DFS事件风险降低27%(HR=0.735,95%CI 0.525-1.028,P=0.0704)。
  • 阿昔替尼组与安慰剂组不良事件发生率99% vs 92%,严重不良事件19% vs 14%,3/4级不良事件61% vs 30%。
  • 总生存数据未成熟。

关键数值与推荐

  • 入组条件:>50%透明细胞肾细胞癌,已行肾切除术,无宏观残留或转移性疾病(IRC确认),≥pT2和/或N+,任何Fuhrman分级,ECOG 0/1。
  • 最高危亚组定义:pT3且FG≥3,或pT4和/或N+(任何T,任何FG)。

临床怎么用

  • 阿昔替尼未能在整体人群中显著改善IRC评估DFS,不推荐作为辅助治疗的标准选择。
  • 最高危亚组中研究者评估DFS改善需谨慎解读,IRC评估未达显著。

局限性

  • 试验因无效提前终止,可能影响统计效能。
  • 总生存数据未成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. PATIENTS AND METHODS: In a phase III, randomized, double-blind trial, patients had >50% clear-cell RCC, had undergone nephrectomy, and had no evidence of macroscopic residual or metastatic disease [independent review committee (IRC) confirmed]. The intent-to-treat population included all randomized patients [≥pT2 and/or N+, any Fuhrman grade (FG), Eastern Cooperative Oncology Group status 0/1]. Patients (stratified by risk group/country) received (1 : 1) oral twice-daily axitinib 5 mg or placebo for ≤3 years, with a 1-year minimum unless recurrence, occurrence of second primary malignancy, significant toxicity, or consent withdrawal. The primary end point was disease-free survival (DFS) per IRC. A prespecified DFS analysis in the highest-risk subpopulation (pT3, FG ≥ 3 or pT4 and/or N+, any T, any FG) was conducted. RESULTS: A total of 724 patients (363 versus 361, axitinib versus placebo) were randomized from 8 May 2012, to 1 July 2016. The trial was stopped due to futility at a preplanned interim analysis at 203 DFS events. There was no significant difference in DFS per IRC [hazard ratio (HR) = 0.870; 95% confidence interval (CI) : 0.660-1.147; P = 0.3211). In the highest-risk subpopulation, a 36% and 27% reduction in risk of a DFS event (HR; 95% CI) was observed per investigator (0.641; 0.468-0.879; P = 0.0051), and by IRC (0.735; 0.525-1.028; P = 0.0704), respectively. Overall survival data were not mature. Similar adverse events (AEs; 99% versus 92%) and serious AEs (19% versus 14%), but more grade 3/4 AEs (61% versus 30%) were reported for axitinib versus placebo. CONCLUSIONS: ATLAS did not meet its primary end point; however, improvement in DFS per investigator was seen in the highest-risk subpopulation. No new safety signals were reported. TRIAL REGISTRATION NUMBER: NCT01599754.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018. PMID: 30346481. doi:10.1093/annonc/mdy454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。